Anti-Mouse IL-4 (Clone 11B11) – Purified in vivo PLATINUM™ Functional Grade

Clone 11B11 is a monoclonal antibody widely used in in vivo studies involving mice to target and neutralize interleukin-4 (IL-4), a cytokine involved in immune responses. Common applications of this antibody in mice include:

1. Neutralization of IL-4 Bioactivity: Clone 11B11 is used to block the biological functions of IL-4 in mouse models. This is crucial for studying the role of IL-4 in immune regulation, inflammation, and autoimmune diseases.

2. Investigation of Immune-Related Pathways: By neutralizing IL-4, researchers can investigate its role in immune responses, including the differentiation of T helper cells and the regulation of antibody production.

3. In Vivo Model Studies: The antibody is used to induce autoimmune-type disorders or to study other immune-related conditions in mice. This involves administering the antibody to mice to modulate their immune responses.

4. Flow Cytometry and Intracellular Staining: Clone 11B11 can be used for detecting intracellular IL-4 levels in mouse cells via flow cytometry. This helps in identifying and enumerating IL-4-producing cells.

In the literature, the 11B11 antibody is often used in conjunction with other antibodies or proteins to study immune responses, particularly in Th2-driven disease models. Here are some commonly used antibodies or proteins that are used alongside 11B11:

1. Anti-IL-5 and Anti-IL-13 Antibodies: These antibodies are used together with 11B11 to understand the role of cytokines in conditions like allergic airway inflammation. They help delineate the specific functions of IL-4, IL-5, and IL-13 in such models.

2. BVD6-24G2 Antibody: This biotinylated antibody is commonly used as a detection antibody in sandwich ELISA assays in conjunction with the 11B11 antibody as a capture antibody for detecting mouse IL-4 levels.

3. Recombinant Mouse IL-4: Used as a standard in ELISA assays to quantify IL-4 levels when 11B11 is used as a capture antibody.

These combinations are crucial for comprehensive analysis of immune responses and cytokine functions in various biological and pathological contexts.

The 11B11 monoclonal antibody is a widely used tool in scientific research, particularly for its ability to neutralize mouse interleukin-4 (IL-4). Key findings from its citations in scientific literature include:

1. Neutralization of IL-4 Bioactivity:

   • The 11B11 antibody effectively neutralizes both natural and recombinant IL-4, which is crucial for studying IL-4's role in immune responses.

2. Impact on Tumor Microenvironment:

   • Neutralization of IL-4 with the 11B11 antibody can alter the tumor microenvironment by reducing tumor-infiltrating CD11b+CD206+ myeloid cells, thereby enhancing the efficacy of tumor-targeted therapies like trastuzumab.

3. Modulation of Immune Responses:

   • IL-4 neutralization affects the myeloid cell compartment, potentially influencing tumor progression and immune responses. However, it does not significantly enhance adaptive immunity or the generation of memory T cells.

4. Role in Allergic Responses and Vaccination:

   • IL-4 is involved in allergic inflammation and blocking IL-4 with 11B11 has been shown to enhance the efficacy of vaccines by reducing IL-4 signaling.

5. Applications in Flow Cytometry:

   • The 11B11 antibody is used in intracellular staining followed by flow cytometric analysis to study IL-4 production in cells such as Th2 polarized and stimulated mouse splenocytes.

Overall, the 11B11 clone is a versatile tool for understanding IL-4's role in immunology and its potential applications in therapeutic strategies.

Dosing regimens of clone 11B11 (anti-mouse IL-4) typically range from 0.01 mg to 1 mg per mouse per dose, with specific protocols differing by mouse model, disease context, and study goal. The most commonly cited standard regimen is 1 mg per mouse via intraperitoneal (i.p.) injection every 4–5 days, but lower doses (as low as 0.01 mg) are also reported, particularly in infectious disease models.

Key variations based on mouse model and disease:

• Tumor models:

  • Standard dosing: 1 mg/mouse, i.p. every 4–5 days, often for multiple doses or a set number such as six total over several weeks.
  • The dosing may be adjusted (lowered or increased) based on mouse strain, tumor type, and the specific tissue targeted.
  • For example, in a HER2+ tumor model, 11B11 was administered every five days for a total of six doses.

• Infectious disease models:

  • Dose ranges from 0.01 mg to 0.4 mg per mouse, administered before or during pathogen challenge.
  • The regimen is adjusted for the severity of infection and mouse susceptibility.

• General immunological or allergic models:

  • Standard regimens are similar to tumor models (1 mg/mouse i.p. every 4–5 days), but the frequency and duration may be altered depending on the desired level or duration of IL-4 blockade.

Factors influencing the choice of regimen:

• Disease model (e.g., tumor, allergy, infection)
• Mouse strain (sensitivity and pharmacokinetics may differ)
• Study endpoints (e.g., acute vs. chronic blockade)
• Body weight (doses in mg/kg may be calculated, though most protocols use per-mouse dosing)

Summary Table of 11B11 Dosing Regimens Across Common Mouse Models:

References indicate that these dosing regimens are highly adaptable, and optimization for a given experiment often involves pilot studies or published precedents for the specific disease context.